[go: up one dir, main page]

ATE189891T1 - Hypolipidämische benzothiazepine - Google Patents

Hypolipidämische benzothiazepine

Info

Publication number
ATE189891T1
ATE189891T1 AT95937940T AT95937940T ATE189891T1 AT E189891 T1 ATE189891 T1 AT E189891T1 AT 95937940 T AT95937940 T AT 95937940T AT 95937940 T AT95937940 T AT 95937940T AT E189891 T1 ATE189891 T1 AT E189891T1
Authority
AT
Austria
Prior art keywords
pct
date
hypolipidemic
benzothiazepines
sec
Prior art date
Application number
AT95937940T
Other languages
English (en)
Inventor
Lawrence Edward Brieaddy
Anthony Louis Handlon
Gordon Lewis Hodgson Jr
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE189891T1 publication Critical patent/ATE189891T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95937940T 1994-11-17 1995-11-16 Hypolipidämische benzothiazepine ATE189891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9423172A GB9423172D0 (en) 1994-11-17 1994-11-17 Hypolipidemic benzothiazepines
PCT/GB1995/002700 WO1996016051A1 (en) 1994-11-17 1995-11-16 Hypolipidemic benzothiazepines

Publications (1)

Publication Number Publication Date
ATE189891T1 true ATE189891T1 (de) 2000-03-15

Family

ID=10764525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937940T ATE189891T1 (de) 1994-11-17 1995-11-16 Hypolipidämische benzothiazepine

Country Status (22)

Country Link
US (1) US5998400A (de)
EP (1) EP0792268B1 (de)
JP (1) JP2868623B2 (de)
KR (1) KR970707111A (de)
CN (1) CN1059674C (de)
AT (1) ATE189891T1 (de)
AU (1) AU706325B2 (de)
BR (1) BR9509683A (de)
CZ (1) CZ147397A3 (de)
DE (1) DE69515183T2 (de)
DK (1) DK0792268T3 (de)
ES (1) ES2144151T3 (de)
FI (1) FI972085A0 (de)
GB (1) GB9423172D0 (de)
GR (1) GR3033450T3 (de)
HU (1) HUT77412A (de)
MX (1) MX9703546A (de)
NO (1) NO308470B1 (de)
NZ (1) NZ295426A (de)
PL (1) PL320093A1 (de)
PT (1) PT792268E (de)
WO (1) WO1996016051A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6190513B1 (en) 1997-05-14 2001-02-20 Applied Materials, Inc. Darkspace shield for improved RF transmission in inductively coupled plasma sources for sputter deposition
GB9704208D0 (en) * 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
GB9800428D0 (en) * 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
CZ20012341A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Corparate Patent Department Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ATE242008T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
US6562860B1 (en) 1998-12-23 2003-05-13 G. D. Searle & Co. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
CA2362147A1 (en) * 1999-02-12 2000-08-17 Steve A. Kolodziej 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
JP2006506464A (ja) * 2002-07-23 2006-02-23 ニュートリノヴァ ニュートリション スペシャリティーズ アンド フード イングリーディエンツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 食事性繊維およびコレステロール低下物質で造られたコレステロール低下剤
US20040147774A1 (en) * 2002-12-20 2004-07-29 Aventis Pharma S.A. Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid
DE10261061A1 (de) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP1775283A4 (de) * 2004-07-14 2008-12-10 Japan Tobacco Inc 3-aminobenzamid-verbindung und hemmer der aktivität des vanilloid-rezeptors 1 (vr1)
NZ552086A (en) * 2004-07-15 2009-12-24 Japan Tobacco Inc Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US9339480B2 (en) * 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP4137137A1 (de) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CN105287604B (zh) 2010-11-08 2019-07-09 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
WO2014144650A2 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
KR101844184B1 (ko) 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
EP3664782B1 (de) 2017-08-09 2025-01-29 Albireo AB Cholestyraminpellets, orale cholestyraminformulierungen und ihre medizinische verwendung
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JOP20200299A1 (ar) 2018-06-20 2020-11-22 Albireo Ab صيغة صيدلانية لأوديفيكسيبات
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7504110B2 (ja) * 2019-02-06 2024-06-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
WO2020161217A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
IL293379A (en) 2019-12-04 2022-07-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
CN114761080B (zh) * 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
EP4551562A1 (de) 2022-07-05 2025-05-14 Albireo AB Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren
CN120265290A (zh) 2022-12-09 2025-07-04 阿尔比里奥公司 治疗肾脏疾病的asbt抑制剂
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59231018A (ja) * 1983-06-10 1984-12-25 Tanabe Seiyaku Co Ltd 抗脂血剤
US4902684A (en) 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
ES2069003T3 (es) * 1989-04-28 1995-05-01 Tanabe Seiyaku Co Procedimiento para preparar derivados de 1,5-benzotiazepina.
GB2255937B (en) * 1991-05-21 1994-11-09 Andrew Thomas Kinnaird Sailboards
GB9111376D0 (en) * 1991-05-25 1991-07-17 Boots Co Plc Therapeutic agents
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
WO1994013651A1 (de) * 1992-12-11 1994-06-23 Ciba-Geigy Ag Benzazepinon-derivate
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
GB9307017D0 (en) * 1993-04-02 1993-05-26 Bp Chem Int Ltd Control of ammonia emission and odour
US5817653A (en) * 1993-08-06 1998-10-06 Smithkline Beecham Corporation Endothelin receptor antagonists
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
GB9704208D0 (en) * 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69515183T2 (de) 2000-08-17
ES2144151T3 (es) 2000-06-01
EP0792268B1 (de) 2000-02-23
CN1059674C (zh) 2000-12-20
PT792268E (pt) 2000-06-30
DK0792268T3 (da) 2000-07-31
NO308470B1 (no) 2000-09-18
NZ295426A (en) 1997-10-24
CZ147397A3 (en) 1997-11-12
KR970707111A (ko) 1997-12-01
JPH11500102A (ja) 1999-01-06
PL320093A1 (en) 1997-09-15
GB9423172D0 (en) 1995-01-04
NO972261D0 (no) 1997-05-16
AU3876295A (en) 1996-06-17
BR9509683A (pt) 1997-09-16
HUT77412A (hu) 1998-04-28
NO972261L (no) 1997-07-16
GR3033450T3 (en) 2000-09-29
MX9703546A (es) 1997-08-30
EP0792268A1 (de) 1997-09-03
DE69515183D1 (de) 2000-03-30
US5998400A (en) 1999-12-07
FI972085L (fi) 1997-05-15
AU706325B2 (en) 1999-06-17
WO1996016051A1 (en) 1996-05-30
JP2868623B2 (ja) 1999-03-10
FI972085A7 (fi) 1997-05-15
FI972085A0 (fi) 1997-05-15
CN1164230A (zh) 1997-11-05

Similar Documents

Publication Publication Date Title
ATE189891T1 (de) Hypolipidämische benzothiazepine
TR200001816T2 (tr) Hipolipidemik benzotiyazepin bileşikleri
DK0626952T3 (da) Hypolipidæmiske benzothiazepinforbindelser
ES2162934T3 (es) Derivados de fenil xantina.
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DE69520364D1 (de) Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ZA953469B (en) New compound
BR9801126A (pt) 1,4-benzotiazepina-1,1-dióxidos hipolipidêmicos.
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
ZA865192B (en) New carboxylic acid derivatives,processes for the preparation thereof,the use thereof and pharmaceutical compositions containing them
BR9507677A (pt) Composto composição farmacéutica processo para a profilaxia ou para o tratamento de condições associadas à inflamação à artrite ou à dor em um mamifero uso do composto processo para a preparação do composto e novo intermediário
GR3025050T3 (en) Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer.
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
ATE196289T1 (de) Neue gylcylanilid-derivate, deren herstellung und deren verwendung zur behandlung von hypercholesterolämie und atherosklerose

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee